

AmerisourceBergen

COVID-19 Therapies Fact Sheet

Updated 3.24.21

Available Therapies

Product	Manufacturer	Ordering Method	Approval	NDC #	AB Item #
Veklury (remdesivir)	Gilead	AB Ordering Platforms (Commercially Available)	FDA Approved	61958-2901-02	10251685
Olumiant (baricitinib)*	Lilly	AB Ordering Platforms (Commercially Available)	Emergency Use Authorization	2mg: 0002-4182-30 1mg: 0002-4732-30	2mg: 10251952 1mg: 10252013
Casirivimab/ Imdevimab	Regeneron	AB Ordering Platforms	Emergency Use Authorization	61755-0036-08	10254336
Bamlanivimab/ Etesevimab	Lilly	AB Ordering Platforms	Emergency Use Authorization	00002-7910-01	10254926
Etesevimab**	Lilly	Dedicated Site	Emergency Use Authorization	00002-7950-01	10254094

*Olumiant (baricitinib) must be ordered from AmerisourceBergen's specialty distribution services for use for the treatment of COVID-19 patients.

**The U.S. Department of Health and Human Services has directed AmerisourceBergen to permit the ordering of etesevimab by itself to compliment already existing bamlanivimab that customers may have on-hand.

Customer sites with sufficient bamlanivimab on hand will now be able to order etesevimab alone. Etesevimab will be ordered in patient courses as are all other products (1 patient course=2 vials of etesevimab).

Customers will have to attest that they have enough bamlanivimab on hand to pair with the number of patient courses of etesevimab they are ordering and that they will administer bamlanivimab with etesevimab as per the EUA.

As of March 24, 2021, the U.S. Department of Health and Human Services announced that given the sustained increase in SARS-CoV-2 viral variants in the United States that are resistant to bamlanivimab administered alone, and the availability of other authorized monoclonal antibody therapies that are expected to retain activity to these variants, the U.S. Government, in coordination with Eli Lilly and Company, will stop the distribution of bamlanivimab alone.

[See Page 2 for Additional Resources and Information](#)

AmerisourceBergen

COVID-19 Therapies Fact Sheet

Updated 3.24.21

Additional Information & Resources

Product	FDA Approval or EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet	FDA Authorization Letter	Additional information regarding product access, dosage, clinical data, etc.
Veklury (remdesivir)	FDA Approval	Healthcare Providers Resources	Patient Support	FDA Authorization Letter	Veklury Website
Olumiant (baricitinib)	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet (ENG) Patient Fact Sheet (SPA)	FDA Authorization Letter	Baricitinib Website
Casirivimab/ Imdevimab	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet	FDA Authorization Letter	Casirivimab/ Imdevimab Website
Bamlanivimab/ Etesevimab	EUA Announcement	Healthcare Providers Fact Sheet	Patient Fact Sheet (ENG) Patient Fact Sheet (SPA)	FDA Authorization Letter	Bamlanivimab/ Etesevimab Website